Risk of venous thromboembolism (VTE) may be higher in patients with cancer who receive chemotherapy.
Thromboprophylaxis with dalteparin is associated with a non-significant decreased risk of venous thromboembolism (VTE).
Among patients with active cancer, full-dose tinzaparin daily compared with warfarin did not significantly reduce the composite measure of recurrent VTE.
Prevalence of occult cancer is low among patients with first unprovoked venous thromboebolism (VTE).
The placement of an inferior vena cava filter is understudied in patients with cancer and clear guidelines do not exist.
Therapeutic anticoagulation is safe for treating venous thromboembolism in patients with cancer that has metastasized to the brain.
Recent research shows that enoxaparin effectively prevents VTE complications in advanced pancreatic cancer without decreasing efficacy of chemotherapy.
Large retroperitoneal lymph node (RPLN) is associated with venous thromboembolism (VTE) in disseminated germ cell tumors (GCTs).
Thromboprophylaxis required throughout hospitalization for most patients with active cancer.
Patients with brain cancer are at increased risk of deep vein thrombosis and consequently pulmonary embolism.
Presence of residual vein thrombosis in cancer patients may help determine the optimal duration of LMWH treatment.
NSAIDs should be prescribed with caution, especially in patients already at a higher risk of VTE.
Independent predictors include older age, chronic steroid use, greater anesthesia time.
Eliquis has been approved for deep vein thrombosis, pulmonary embolism, and reduction of risk for both.
A review of data suggests that HPV testing alone every 3 years provides a high level of reassurance against cervical cancer.
While guidelines recommend against routine use, further investigation and data collection on this topic is warranted.
Registry data show increase in incidence rates of HPV-related oropharyngeal and anal cancers.
Risk for venous thromboembolism appears to be no higher after quadrivalent HPV vaccination.
List of medications indicated for the prophylaxis and/or treatment of deep vein thrombosis (DVT) / pulmonary embolism (PE) with usual adult dosage.
The rate of venous thromboembolism is higher than previously reported in retrospective studies.
New cancer therapies and statins demonstrate efficacy in treating and perhaps even preventing ovarian cancer recurrence.
Tumor emboli can occur in patients with cancer and carry with them a risk for serious complications.
Major challenges exist for hospitals with respect to publicly reported cancer metrics, according to research presented at SSO 2013.
Oncologists should be aware of possible complications associated with administering anticoagulants to patients with cancer.
VEGF Receptor TKIs Not Associated with Increased Risk of Venous Thrombotic Events, Meta-Analysis FindsJanuary 15, 2013
Vascular endothelial growth factor receptor tyrosine-kinase inhibitors do not appear to be associated with an increased risk of venous thrombotic events in patients with advanced cancers.
Global experts called on colleagues attending the 54th American Society of Hematology Annual Meeting and Exposition to help disseminate and implement the first International Good Clinical Practice Guidelines for the use of antithrombotics.
Patients with advanced solid tumors treated with cisplatin have a significant increased risk of venous thromboembolism compared with non-cisplatin-based chemotherapy.
Erythropoietin stimulating agents and granulocyte colony stimulating factor do not affect OS among patients with ovarian cancer who receive bevacizumab plus chemotherapy, but ESA is associated with a significantly-elevated risk of venous thrombotic events.
Unsuspected PE patients also have similar risk of recurrent VTE as those with clinically suspected PE.
Dr. E. David Crawford, Head Urologic Oncology at the University of Colorado, presents his case study on renal cell carcinoma (RCC).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy